Anemia and Kidney Disease
Part of NephTimes
Advertisement
A team analyzed sotagliflozin's effects on hemoglobin in patients with stage 3-4 CKD and type 2 diabetes.
The TRANSNEMIA study addressed the need for guidelines specific to anemia in kidney transplant recipients.
A study examined the efficacy and safety of conversion from treatment with the long-acting ESA MPG-EPO to vadadustat.
Individualized dosing of ESAs using anemia therapy assistance software improved hemoglobin stability and ESA utilization.
Researchers examined the long-term safety of oral hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia of CKD.
Under a new agreement with Akebia, US Renal Care will be able to prescribe Vafseo to dialysis patients with anemia of CKD.
Anemia of CKD in China and its related health care costs are projected to rise, but earlier screening and treatment can help.
A recent study compared anemia diagnosis and treatment in older patients hospitalized in nephrology versus geriatric units.
How does early vs delayed treatment with long-acting ESAs affect renal and cardiovascular outcomes in patients with NDD-CKD?
Researchers used KPIs to evaluate anemia and iron status management in children on hemodialysis.
A study examined the prevalence of iron deficiency and associated factors in patients with stage 4-5 CKD.
A study examined the effect of an egg white diet in relation to anemia in patients with end-stage renal disease on dialysis.
Akebia Therapeutics has ended its license agreement with CSL Vifor for Vafseo and announced WAC pricing for the anemia drug.
A study examined the effect of C-reactive protein on the efficacy of HIF-PHIs for anemia with CKD.
Kidney transplant recipients may be at a higher risk of developing parvovirus B19-related complications.
Iron replacement with ferric citrate hydrate decreased cFGF23 and normalized platelet count with anemia regardless of CKD.
Anemia and iron metabolism disorders can affect the evaluation process for kidney transplantation.
Researchers examined the roles of hyperuricemia and anemia in all-cause mortality with chronic kidney disease (CKD).
The ERA reviewed phase 3 trials to clarify the mechanism behind HIF-PHi and their role in managing CKD-related anemia.
The FDA approved Vafseo (vadadustat) to treat anemia due to chronic kidney disease (CKD) in adults on dialysis.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.